MARKET OUTLOOK
The Triton Market Research report states that the Asia-Pacific hyperphosphatemia drugs market is expected to grow in terms of revenue with a CAGR of 17.86% during the forecast period 2019 to 2027.
The countries of India, China, Japan, South Korea, Australia & New Zealand, ASEAN countries and countries in rest of APAC together constitute the market for hyperphosphatemia drugs in the Asia-Pacific region.
The growth of Asia-Pacific hyperphosphatemia drugs market can majorly be attributed to the growing aging populace, increase in the cases of osteoporosis and the changing dietary habits of people. Amongst these, the high prevalence of osteoporosis is the major driver for the hyperphosphatemia drugs market in this region. Osteoporosis is significantly undertreated and underdiagnosed in this region, even in the high-risk patients who have experienced previous fractures. In Asia-Pacific’s most populated countries such as India and China, hip fractures are frequently treated conventionally at their house as an alternative to surgical treatment in hospitals.
Whereas, the changing dietary habits of people have led to the hyperphosphatemia drug market growth in Australia. The increased phosphate levels in the body give rise to hyperphosphatemia. High phosphate-containing foods are meat, dairy items, fast food, soft drinks, nuts, seeds, chocolates and processed food. The consumption of these food items increases the phosphorous level in the body, eventually leading to diseases such as hyperphosphatemia. Thus, the changing dietary habits and a shift from functional foods to processed foods are mainly responsible for causing hyperphosphatemia in the region.
COMPETITIVE OUTLOOK
Top companies that have been studied in the market are Shire, Zeria Pharmaceutical, Sanofi, Royal DSM N.V., Keryx Biopharmaceuticals, Inc., Sun Pharmaceutical Industries, Ltd., Bruno Farmaceutici S.p.A., Fermenta Biotech, Ltd., Roche Diagnostics Corporation, Cipla, Bio-Tech Pharmacal, Fresenius Medical Care, Johnson and Johnson, Pfizer, Inc., AMAG Pharmaceuticals and Ultragenyx Pharmaceutical, Inc.